Dianthus Therapeutics, Inc. /DE/ Other Income and Expense
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Other Income and Expense of $11.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for the quarter ending 2026-06-30 was $11.27M, a 241.63% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for the quarter ending 2026-03-31 was $5.70M, a 55.46% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for the quarter ending 2025-12-31 was $5.11M, a 46.98% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for the quarter ending 2025-09-30 was $3.52M, a 25.45% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for fiscal 2025 was $15.60M, a 7.69% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for fiscal 2024 was $16.89M, a 265.77% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for fiscal 2023 was $4.62M, a 275.83% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ nonoperating income (expense) for fiscal 2022 was $1.23M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.27M 10-Q · filed 2026-08-04 | $16.97M 10-Q · filed 2026-08-04 | $22.07M derived: sum of 3 quarters · filed 2026-08-04 | $25.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $5.70M 10-Q · filed 2026-05-05 | $10.81M derived: sum of 2 quarters · filed 2026-05-05 | $14.33M derived: sum of 3 quarters · filed 2026-05-05 | $17.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.63M derived: sum of 2 quarters · filed 2026-03-09 | $11.93M derived: sum of 3 quarters · filed 2026-08-04 | $15.60M 10-K · filed 2026-03-09 |
| 2025-09-30 | $3.52M 10-Q · filed 2025-11-05 | $6.82M derived: sum of 2 quarters · filed 2026-08-04 | $10.49M 10-Q · filed 2025-11-05 | $13.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.30M 10-Q · filed 2026-08-04 | $6.96M 10-Q · filed 2026-08-04 | $10.44M derived: sum of 3 quarters · filed 2026-08-04 | $15.17M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.67M 10-Q · filed 2026-05-05 | $7.14M derived: sum of 2 quarters · filed 2026-05-05 | $11.87M derived: sum of 3 quarters · filed 2026-05-05 | $16.46M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.20M derived: sum of 2 quarters · filed 2026-03-09 | $12.80M derived: sum of 3 quarters · filed 2026-03-09 | $16.89M 10-K · filed 2026-03-09 |
| 2024-09-30 | $4.73M 10-Q · filed 2025-11-05 | $9.32M derived: sum of 2 quarters · filed 2025-11-05 | $13.42M 10-Q · filed 2025-11-05 | $15.81M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.60M 10-Q · filed 2025-08-07 | $8.69M 10-Q · filed 2025-08-07 | $11.09M derived: sum of 3 quarters · filed 2025-08-07 | $12.08M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.10M 10-Q · filed 2025-05-12 | $6.49M derived: sum of 2 quarters · filed 2025-05-12 | $7.49M derived: sum of 3 quarters · filed 2025-05-12 | $8.12M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.39M derived: sum of 2 quarters · filed 2025-03-11 | $4.03M derived: sum of 3 quarters · filed 2025-03-11 | $4.62M 10-K · filed 2025-03-11 |
| 2023-09-30 | $996.00K 10-Q · filed 2024-11-07 | $1.63M derived: sum of 2 quarters · filed 2024-11-07 | $2.23M 10-Q · filed 2024-11-07 | $2.80M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $636.00K 10-Q · filed 2024-08-08 | $1.23M 10-Q · filed 2024-08-08 | $1.81M derived: sum of 3 quarters · filed 2024-08-08 | $2.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $594.00K 10-Q · filed 2024-05-09 | $1.17M derived: sum of 2 quarters · filed 2024-05-09 | $1.64M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $577.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.05M derived: sum of 2 quarters · filed 2024-03-21 | $1.23M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $470.00K 10-Q · filed 2023-11-09 | $652.00K 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | -$23.00K 8-K · filed 2023-12-21 | |||
| 2018-12-31 | $2.45M 10-K · filed 2019-03-19 | |||
| 2017-12-31 | $236.00K 10-K · filed 2019-03-19 | |||
| 2016-12-31 | -$163.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |